All Videos

A dermatology expert reviews findings from a recently presented study on using other atopic dermatitis (AD) treatments within six months of initiating ruxolitinib cream. The expert assesses ruxolitinib's effectiveness and potential role in treatment, highlighting the need for further research on its long-term implications in AD management.

Focusing on pregnant patients with atopic dermatitis who are treatment naïve, Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, discuss best practices for informing patients on the available treatment options for this condition.

Jenny Murase, MD, provides a brief overview of the Fc receptor and the role of transcription binding in atopic dermatitis.

Mickey Bryson recounts how Kristine Kucera, PA-C, MPAS, DHS, introduced a new medication and shared trial data with him, empowering him to make an informed decision about trying the new treatment.

James Del Rosso, DO, continues the discussion on managing acne in a female patient, emphasizing how to balance patient expectations and optimize skincare regimens, particularly when underlying conditions like polycystic ovarian syndrome are present.

An acne management expert discusses the importance of understanding patients' dietary choices on treatment outcomes, reviewing the different types of isotretinoin and highlighting the crucial role of micronized or food-independent formulations in effective acne care.

James Del Rosso, DO, presents the case of a 14-year old female suffering from mild to moderate acne and explores the role of isotretinoin, optimizing adolescent treatment protocols, and the rationale behind initial therapies such as oral antibiotics in similar cases.

Hilary Baldwin, MD, presents a case study of a 17-year-old high school student with moderate acne vulgaris on her face and back, which caused significant emotional distress and lowered self-esteem, and discusses the patient's treatment journey and the resolution achieved.

Hilary Baldwin, MD, a dermatologist, presents a case study of a 12-year-old overweight male patient with a two-year history of moderate facial acne, discussing her diagnostic process and recommended treatment plan.

Lawrence Eichenfield, MD, explores the significant comorbidities and conditions, such as allergic rhinitis, anxiety, and asthma, that intersect with atopic dermatitis (AD), discussing their influence on disease management and treatment response, as well as the observed treatment patterns of patients with this condition before and after the initiation of ruxolitinib therapy.

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Jenny Murase, MD, describes how rising estrogen levels cause a shift in immune response from Th1 to Th2, causing potential atopic dermatitis exacerbations for patients who are pregnant.

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's negative treatment outcomes and explore alternative options, such as switching to a psoriasis-specific medication, emphasizing the short-lived 2-week relief followed by symptom recurrence, which left Mickey resigned to the disease but still seeking a resolution.

An expert in the management of dermatological conditions shares insights on managing atopic dermatitis patients, discussing the real-world effectiveness and physician satisfaction with ruxolitinib cream as a treatment option, as well as its adoption among healthcare providers.

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dr. Elizabeth Kiracofe, MD, FAAD, and Dr. Jenny Murase, MD, introduce a discussion on the undertreatment of patients with atopic dermatitis, particularly focusing on pregnant individuals and those of childbearing age.

Kristine Kucera, PA-C, MPAS, DHS, discusses prescribing a PDE-4 inhibitor for Mickey Bryson's psoriasis and atopic dermatitis, emphasizing the absence of FDA-approved medications like JAK inhibitors, while Bryson underscores the challenges of daily injections, likening it to insulin use.

Continuing the discussion on the case of a 17-year-old patient with moderate acne, Heather Woolery-Lloyd, MD, FAAD, provides an overview of the utilization of clascoterone cream, highlighting the application process and its unique mechanism of action.

An expert dermatologist presents the case of a 17-year-old with moderate acne, and discusses the importance of the proper application layering of skin care and prescription products to optimize treatment efficacy.

Highlighting ways to maximize absorption of isotretinoin, Heather Woolery-Lloyd, MD, FAAD provides insights on dietary considerations and the role of micronized and food independent isotretinoin.

Heather Woolery-Lloyd, MD, FAAD reviews the case of a 12-year-old patient with moderate-to-severe acne, focusing on how to navigate appropriate treatment decisions and patient factors that indicate when a patient is an ideal candidate for isotretinoin.

Rocco Serrao, MD, FAAD, addresses potential barriers to access and affordability of narrowband UVB phototherapy and topical medications for vitiligo treatment, while highlighting available resources to assist patients in overcoming these obstacles.

Rocco Serrao, MD, FAAD, discusses a case of a 38-year-old male with progressive vitiligo, exploring potential triggers and exacerbating factors, as well as lifestyle changes and treatment options to manage symptoms and improve quality of life.

Dr Serrano, shares insights on the panel’s advice given to their patients with vitiligo who have achieved remission through treatment with ruxolitinib, while also addressing the challenges of navigating payer coverage for vitiligo treatments and strategies for dealing with coverage denials.

Rocco Serrao, MD, FAAD, a board-certified dermatologist, discusses a case of vitiligo involving a 20-year-old male patient who presents with white patches on his face that have persisted for 6 weeks without any relevant chemical exposures, and emphasizes the importance of providing counseling and support to address the potential impact on the patient's self-esteem and confidence.

In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's atopic dermatitis diagnostic process and the ineffective initial treatments, which included topical therapies, homeopathic remedies, and prednisone steroids.

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative.

Dr. Matthew J. Zirwas, evaluates a 45-year-old woman with worsening, highly itchy dermatitis on her hands and arms, notably her fingertips. He addresses management strategies for her condition, which has deteriorated over four months, leading to painful fissures

Matthew J. Zirwas, MD, , presents a complex case study of a 63-year-old male patient with atopic dermatitis presenting as a chronic, severe pruritic rash on his back, upper arms, and upper thighs. His condition has persisted consistently for the past three months despite a history of intermittent occurrences over several years.